NEURACAP

Research reports, page 5

Sector outlooks, company valuation reports and M&A updates on public markets.

For information only. Not an appraisal or a fairness opinion.

404 reports · page 5 of 17

Browse by sector →
Cover of Life Sciences Research Reagents and Supplies Sector Outlook — September 2026Sector Outlook

Health Care

Life Sciences Research Reagents and Supplies Sector Outlook — September 2026

This report values nine public life sciences research reagents and supplies companies on EV/Revenue (CY2027E), maps segment and growth-based valuation tiers, and reviews recent precedent transactions. Built for corporate development, strategy and finance teams assessing where this market pays a premium.

Life Sciences Research Reagents and Supplies · 21 pages · Free to read

Cover of Consumer Finance Sector Outlook — September 2026Sector Outlook

Financials

Consumer Finance Sector Outlook — September 2026

A sector-wide look at how public markets price 20 rated consumer finance lenders on forward earnings, why one non-prime segment spans a wide valuation range, and what six recent precedent transactions suggest buyers are actually acquiring. For owners, boards and acquirers assessing where they sit.

Consumer Finance · 21 pages · Free to read

Cover of Contract Research Organizations (CRO) Sector Outlook — September 2026Sector Outlook

Health Care

Contract Research Organizations (CRO) Sector Outlook — September 2026

A September 2026 sector outlook on Contract Research Organizations, covering eleven public companies' forward revenue valuations, nine precedent transactions with disclosed terms, and what the two-price-band pattern means for owners, buyers and boards.

Contract Research Organizations (CRO) · 21 pages · Free to read

Cover of Contract Development and Manufacturing (CDMO) Sector Outlook — September 2026Sector Outlook

Health Care

Contract Development and Manufacturing (CDMO) Sector Outlook — September 2026

A sector-wide review of the 11 listed contract development and manufacturing companies, covering EV/Revenue (CY2027E) valuation, recorded precedent transactions, and the operating choices tied to price. Built for owners, acquirers and boards assessing CDMO positioning and capacity strategy.

Contract Development and Manufacturing (CDMO) · 21 pages · Free to read

Cover of Therapeutic Discovery Platforms M&A update, 14–28 September 2026M&A Update

Health Care

Therapeutic Discovery Platforms M&A update, 14–28 September 2026

A bi-weekly read on Therapeutic Discovery Platforms covering public market moves, major news catalysts and M&A activity for September 14–28, 2026, built for operators, acquirers and advisors tracking valuation and strategy shifts across covered platforms.

Therapeutic Discovery Platforms · 7 pages · Free to read

Cover of Antibody and Protein Therapeutics M&A update, 14–28 September 2026M&A Update

Health Care

Antibody and Protein Therapeutics M&A update, 14–28 September 2026

A bi-weekly read on antibody and protein therapeutics: share-price moves, company catalysts and transaction activity across 58 covered names for September 14–28, 2026. Built for operators, acquirers and advisors tracking how clinical and regulatory evidence is repricing the sector.

Antibody and Protein Therapeutics · 7 pages · Free to read

Cover of Therapeutic Discovery Platforms Sector Outlook — September 2026Sector Outlook

Health Care

Therapeutic Discovery Platforms Sector Outlook — September 2026

A sector outlook on Therapeutic Discovery Platforms companies, covering how the public market prices seven clinical-stage platform companies on EV / Revenue (CY2027E), what precedent transactions reveal about buyer behavior, and the capital-allocation questions this pricing raises for platform owners and acquirers.

Therapeutic Discovery Platforms · 21 pages · Free to read

Cover of Vaccines Sector Outlook — September 2026Sector Outlook

Health Care

Vaccines Sector Outlook — September 2026

NeuraCap's Vaccines sector outlook: who plays, how the market prices them, what has transacted, and what it means for owners, operators and acquirers.

Vaccines · 20 pages · Free to read

Cover of Antibody and Protein Therapeutics Sector Outlook — September 2026Sector Outlook

Health Care

Antibody and Protein Therapeutics Sector Outlook — September 2026

This report maps the Antibody and Protein Therapeutics sector into three EV / Revenue (CY2027E) valuation tiers across 63 companies, examines what separates the top of the range from the bottom, and reviews nine precedent transactions. Built for boards, owners and corporate development teams tracking this space.

Antibody and Protein Therapeutics · 22 pages · Free to read

Cover of Regenerative Medicine M&A update, 14–28 September 2026M&A Update

Health Care

Regenerative Medicine M&A update, 14–28 September 2026

A bi-weekly briefing on Regenerative Medicine industry events, public-market movers and M&A activity for September 14–28, 2026, covering seven public names, sector-wide regulatory catalysts and the trailing precedent-transaction record, for operators, acquirers and advisors tracking sector direction.

Regenerative Medicine · 7 pages · Free to read

Cover of Cell and Gene Therapies M&A update, 14–28 September 2026M&A Update

Health Care

Cell and Gene Therapies M&A update, 14–28 September 2026

This bi-weekly update tracks public market moves, major news and M&A activity across 43 covered cell and gene therapy companies for September 14–28, 2026. It is built for operators, acquirers and advisors who need a fast, sourced read on what changed, who moved and what closed.

Cell and Gene Therapies · 7 pages · Free to read

Cover of Rare and Orphan Disease Therapeutics M&A update, 14–28 September 2026M&A Update

Health Care

Rare and Orphan Disease Therapeutics M&A update, 14–28 September 2026

This bi-weekly report tracks price moves, company news, and M&A activity across rare and orphan disease therapeutics companies for September 14–28, 2026, for investors, operators and advisers who need a fast read on what changed and why it matters.

Rare and Orphan Disease Therapeutics · 7 pages · Free to read

Cover of Regenerative Medicine Sector Outlook — September 2026Sector Outlook

Health Care

Regenerative Medicine Sector Outlook — September 2026

This report covers the Regenerative Medicine sector as of September 2026 — implants, instrumentation, therapeutics and adjacent models — using EV/EBITDA (CY2027E) as the primary valuation lens alongside precedent transaction evidence, for teams assessing portfolio strategy and positioning.

Regenerative Medicine · 20 pages · Free to read

Cover of Cell and Gene Therapies Sector Outlook — September 2026Sector Outlook

Health Care

Cell and Gene Therapies Sector Outlook — September 2026

This report maps the Cell and Gene Therapies sector into platform developers and commercial-stage supply, using EV/Revenue (CY2027E) across 47 companies and nine precedent transactions. It is written for owners, management teams and capital partners assessing where value sits in this range.

Cell and Gene Therapies · 22 pages · Free to read

Cover of Rare and Orphan Disease Therapeutics Sector Outlook — September 2026Sector Outlook

Health Care

Rare and Orphan Disease Therapeutics Sector Outlook — September 2026

This report compares valuation and deal activity across public rare and orphan disease therapeutics companies, contrasting pipeline-stage and commercial orphan models. It supports investors, corporate development teams and boards assessing capital allocation and strategic options in the sector.

Rare and Orphan Disease Therapeutics · 23 pages · Free to read

Cover of Ophthalmic Therapeutics M&A update, 14–28 September 2026M&A Update

Health Care

Ophthalmic Therapeutics M&A update, 14–28 September 2026

A bi-weekly update on Ophthalmic Therapeutics covering public market moves, major regulatory and legal catalysts, and M&A activity across 12 covered names for September 14–28, 2026. Built for operators, acquirers and advisors tracking the sector's clinical readout calendar and deal record.

Ophthalmic Therapeutics · 7 pages · Free to read

Cover of Neurology and CNS Therapeutics M&A update, 14–28 September 2026M&A Update

Health Care

Neurology and CNS Therapeutics M&A update, 14–28 September 2026

This bi-weekly update tracks Neurology and CNS Therapeutics stocks, news flow and M&A across September 14–28, 2026, for investors, operators and advisors who need a fast read on what moved, why, and what closed.

Neurology and CNS Therapeutics · 7 pages · Free to read

Cover of Immunology and Inflammation Therapeutics M&A update, 14–28 September 2026M&A Update

Health Care

Immunology and Inflammation Therapeutics M&A update, 14–28 September 2026

This bi-weekly update tracks share-price moves, major news catalysts and M&A activity across Immunology and Inflammation Therapeutics from September 14–28, 2026, for operators, acquirers and advisors monitoring sector positioning and deal flow.

Immunology and Inflammation Therapeutics · 7 pages · Free to read

Cover of Oncology Therapeutics M&A update, 14–28 September 2026M&A Update

Health Care

Oncology Therapeutics M&A update, 14–28 September 2026

A bi-weekly review of oncology therapeutics market moves, regulatory catalysts and M&A activity for September 14–28, 2026, covering 47 public names and the trailing precedent transaction set — built for operators, acquirers and advisors tracking the sector.

Oncology Therapeutics · 7 pages · Free to read

Cover of Ophthalmic Therapeutics Sector Outlook — September 2026Sector Outlook

Health Care

Ophthalmic Therapeutics Sector Outlook — September 2026

A sector-wide look at ophthalmic therapeutics: how the market prices thirteen clinical-stage programme owners against one sterile ophthalmic supply business, where public valuations sit on forward revenue, and how recorded transactions priced products versus programmes.

Ophthalmic Therapeutics · 20 pages · Free to read

Cover of Neurology and CNS Therapeutics Sector Outlook — September 2026Sector Outlook

Health Care

Neurology and CNS Therapeutics Sector Outlook — September 2026

This sector outlook examines how public markets and precedent transactions value Neurology and CNS Therapeutics companies, distinguishing clinical-stage, specialty and diversified franchise business models for investors and corporate development teams.

Neurology and CNS Therapeutics · 21 pages · Free to read

Cover of Immunology and Inflammation Therapeutics Sector Outlook — September 2026Sector Outlook

Health Care

Immunology and Inflammation Therapeutics Sector Outlook — September 2026

This report maps Immunology and Inflammation Therapeutics companies by business model, benchmarks forward revenue valuations, and reviews precedent transactions. It is for investors, corporate development teams and boards weighing where premium multiples are earned and what supports them.

Immunology and Inflammation Therapeutics · 20 pages · Free to read

Cover of Oncology Therapeutics Sector Outlook — September 2026Sector Outlook

Health Care

Oncology Therapeutics Sector Outlook — September 2026

An Oncology Therapeutics sector outlook covering business segments, EV / Revenue (CY2027E) valuation, precedent transactions and strategic implications, for investors and corporate development teams assessing where clinical evidence and commercial durability drive value, as of September 2026.

Oncology Therapeutics · 22 pages · Free to read

Cover of Biotechnology M&A update, 14–28 September 2026M&A Update

Health Care

Biotechnology M&A update, 14–28 September 2026

A bi-weekly read on biotechnology: which of 74 covered names moved, what companies disclosed, and which deals crossed the record for September 14–28, 2026. Built for operators, acquirers and advisors tracking sector catalysts and M&A activity.

Biotechnology · 7 pages · Free to read

Need this for your own company?

Company valuation reports are built on the same evidence base as the research above — public or private, any sector.